New agents in post-remission therapy

Best Practice and Research: Clinical Haematology

Volumn 23, Issue 4, 2010, Pages 475-479

  Stone, Richard M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Acute myeloid leukemia; AML; Cell signaling modulation; High dose ara C; Immunotherapy; Older adults; Post remission; Younger adults

Indexed keywords

BORTEZOMIB; CYCLOSPORIN A; CYTARABINE; DAUNORUBICIN; FLT3 LIGAND; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LENALIDOMIDE; MITOMYCIN C; NUCLEOPHOSMIN; PROTEIN TYROSINE KINASE INHIBITOR; THALIDOMIDE; VALSPODAR;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CONTINUOUS INFUSION; CYTOGENETICS; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; IMMUNOSTIMULATION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

ADULT; AGE FACTORS; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CYTARABINE; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; REMISSION INDUCTION; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 78649922684     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2010.09.004     Document Type: Review

References (25)

1. C.D. Bloomfield, G.P. Herzig, and B.A. Peterson Long-term survival of patients with acute myeloid leukemia: updated results from two trials evaluating postinduction chemotherapy Cancer 80 1997 2186 2190
2. P.A. Cassileth, C.B. Begg, and J.M. Bennett A randomized study of the efficacy of consolidation therapy in adult acute nonlymphocytic leukemia Blood 63 1984 843 847
3. S.N. Wolff, J. Marion, and R.S. Stein High-dose cytosine arabinoside and daunorubicin as consolidation therapy for acute nonlymphocytic leukemia in first remission: a pilot study Blood 65 1985 1407 1411
4. R.J. Mayer, R.B. Davis, and C.A. Schiffer Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B N Engl J Med 331 1994 896 903
5. H.F. Fernandez, Z. Sun, and X. Yao Anthracycline dose intensification in acute myeloid leukemia N Engl J Med 361 2009 1249 1259
6. C.D. Bloomfield, D. Lawrence, and J.C. Byrd Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype Cancer Res. 58 1998 4173 4179
7. P. Paschka, G. Marcucci, and A.S. Ruppert Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol 24 2006 3904 3911 (Pubitemid 46630738)
8. J.O. Moore, S.L. George, and R.K. Dodge Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222 Blood 105 2005 3420 3427
9. A. Neubauer, K. Maharry, and K. Mrozek Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study J Clin Oncol 26 2008 4603 4609
10. R.F. Schlenk, K. Dohner, and J. Krauter Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia N Engl J Med 358 2008 1909 1918
11. K. Dohner, R.F. Schlenk, and M. Habdank Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations Blood 106 2005 3740 3746
12. J.C. Byrd, A.S. Ruppert, and K. Mrozek Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461 J Clin Oncol 22 2004 1087 1094
13. E.H. Estey, M.J. Keating, and K.B. McCredie Cellular ara-CTP pharmacokinetics, response, and karyotype in newly diagnosed acute myelogenous leukemia Leukemia 4 1990 95 99
14. B. Lowenberg, S. Suciu, and E. Archimbaud Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy-the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group J Clin Oncol 16 1998 872 881
15. P. Fenaux, G.J. Mufti, and E. Hellstrom-Lindberg Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia J Clin Oncol 28 2010 562 569
16. T.A. Fehniger, J.C. Byrd, and G. Marcucci Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13 Blood 113 2009 1002 1005
17. A.K. Burnett, R.K. Hills, and C. Green The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA Blood 115 2010 948 956
18. R.F. Schlenk, S. Frohling, and F. Hartmann Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia Leukemia 18 2004 1798 1803
19. E.J. Feldman, J. Brandwein, and R. Stone Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia J Clin Oncol 23 2005 4110 4116
20. B. Lowenberg, J. Beck, and C. Graux Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study Blood 115 2010 2586 2591
21. M.R. Baer, S.L. George, and M.A. Caligiuri Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720 J Clin Oncol 26 2008 4934 4939
22. J.E. Kolitz, V. Hars, and D.J. DeAngelo Phase III trial of immunotherapy with recombinant interleukin-2 (rIL-2) versus observation in patients <60 years with acute myeloid leukemia (AML) in first remission (CR1): preliminary results from Cancer and Leukemia Group B (CALGB) 19808 Blood 110 2007 53a [abstract 157]
23. M. Brune, S. Castaigne, and J. Catalano Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial Blood 108 2006 88 96
24. J.F. DiPersio, R.H. Collins, and W. Blum Immune responses in AML patients following vaccination with GRNVAC1, autologous RNA transfected dendritic cells expressing telomerase catalytic subunit hTERT Blood 114 2009 262 [abstract 633]
25. R.M. Stone, T. Fischer, and R. Paquette A phase 1b study of midostaurin (PKC412) in combination with daunorubicin and cytarabine induction and high-dose cytarabine consolidation in patients under age 61 with newly diagnosed de novo acute myeloid leukemia: Overall survival of patients whose blasts have FLT3 mutations is similar to those with wild-type FLT3 Blood 114 2009 263 [abstract 634]